#73 Novel Oral Anti-coagulants (NOACs): is newer better?
CLINICAL QUESTION
For patients with non-valvular atrial fibrillation (AF), do the NOACs (dabigatran, rivaroxaban, apixaban) have advantages over warfarin?
BOTTOM LINE
Compared to warfarin, NOACs offer some benefits for patients with non-valvular atrial fibrillation. The decision to use a NOAC or warfarin should be made after reviewing the patient’s previous INR stability, kidney function and discussing the potential benefits and risks, direct and indirect costs with the patient.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
All randomized controlled trials compared NOACs to warfarin: patients mean age 70-73 years, 35-40% female, 1.8-2 years follow-up. All outcomes versus warfarin:
- Dabigatran: 150mg BID or 110mg BID,1,2 18, 113 patients, mean CHADS2=2.1.
- Stroke & systemic embolism:
- 150mg: 0.60% less/year, Number Needed to Treat (NNT)=167.
- 110 mg: No statistical difference.
- Major Bleed:
- 150mg: No statistical difference.
- 110mg: 0.70% less/year, NNT=143.
- o Mortality:
- 150mg: Borderline significance [p=0.051, absolute difference would be 0.49% less/year, NNT=205].
- 110mg: No statistical difference.
- Stroke & systemic embolism:
- • Rivaroxaban: 20mg QD,3 14,264 patients, mean CHADS2=3.5.
- Stroke & systemic embolism, major bleed, or mortality: No statistical difference.
- • Apixaban: 5mg BID,4 18,201 patients, mean CHADS2=2.1
- Stroke & systemic embolism: 0.33% less/year, NNT=303.
- Major Bleed: 0.96% less/year, NNT=104.
- Mortality: 0.42% less/year, NNT=238.
- While statistical significance was achieved in some endpoints, whether clinically meaningful differences exist between the agents is unknown.
- In Canada, only dabigatran and rivaroxaban are currently approved for AF stroke prevention.
- Appropriate patient selection important:
- Use CHADS2, time in therapeutic INR range, and tools http://www.vhpharmsci.com/sparc/ to aid discussion.
- NOACs contra-indicated in patients with significant renal impairment (CrCl < 30 mL/min), use lower doses if moderate renal impairment (CrCl 30-50 mL/min).5
- Major bleeding occurs with all anticoagulants:
- NOACs: no established reversal strategy.
- Bleeding risk factors: (primarily from dabigatran experience): age > 80 years, impaired6 or deteriorating renal function5, < 60 kg6, and starting before INR < 2.0.6
- Potential risk of myocardial infarction (dabigatran): Number Needed to Harm (NNH)=250-500.1,2,7
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
This needs to be updated since apixaban is approved in Canada and reversal agents do exist for NOACS
Interesting.